About Bioenvision
Bioenvision is a Healthcare company based in New York (United States) founded in 1996, and was acquired by Genzyme in May 2007. Acquisition, development, and marketing of compounds and technologies for the treatment of cancer. Bioenvision has raised $7.4 million across 1 funding round from investors including Genzyme. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Bioenvision (Previously Ascot Group) engages in the acquisition, development, and marketing of compounds and technologies primarily for the treatment of cancer. Its lead products include Evoltra (clofarabine) which has marketing approval in both the European Union and the United States for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia and Modrenal (trilostane), which has marketing approval in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy. It was acquired by Genzyme Corporation in Oct, 2007.
- Headquarters New York, United States
- Stage Acquired
- SectorsHealthcare
- Website bioenvision.com
- Acquired by Genzyme (May 2007)
Funding Insights of Bioenvision
Bioenvision has successfully raised a total of $7.4M through 1 strategic funding round. The most recent funding activity was a Series A round of $7.4 million completed in May 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.4M
- Total Rounds 1
- Last Round Series A — $7.4M
- First Round $7.4M
(May 2007)
All 1 funding rounds of Bioenvision with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2007 | $7.4M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Bioenvision
Bioenvision has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Genzyme.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biopharmaceutical products for rare genetic diseases are developed and supplied. | 1996 | genzyme.com | Boston, United States |
Investor details for Bioenvision
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Bioenvision
3 dated milestones of Bioenvision across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Bioenvision is founded.
- Funding First funding round of $7.4M.
- Exit Acquired by Genzyme.
Competitors of Bioenvision
Bioenvision has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Bioenvision
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Bioenvision (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bioenvision
Complete news archive for Bioenvision
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bioenvision
Bioenvision was founded in 1996 and raised its 1st funding round 11 years after it was founded.
Bioenvision is headquartered in New York, United States. It is registered at New York, New York, United States.
Bioenvision is a funded company, having raised a total of $7.4M across 1 funding round to date. The company's 1st funding round was a Series A of $7.4M, raised on May 2007.
Bioenvision (Previously Ascot Group) engages in the acquisition, development, and marketing of compounds and technologies primarily for the treatment of cancer. Its lead products include Evoltra (clofarabine) which has marketing approval in both the European Union and the United States for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia and Modrenal (trilostane), which has marketing approval in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy. It was acquired by Genzyme Corporation in Oct, 2007.
Bioenvision has 1 investor. Key investors include Genzyme.
Yes. Bioenvision was acquired by Genzyme in May 2007.